Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
PRF TechnologiesPRFX -2.38%22 1-Year ROIIC % is 528.05 as of Jun. 2026. GuruFocus rates PRFX with a GF Score™ of 22/100. The stock has 1 warning sign investors should review. Among 828 Drug Manufacturers companies, PRF Technologies ranks better than 96.14% on this metric.
1-Year Return on Invested Incremental Capital (1-Year ROIIC %) measures the change in earnings as a percentage of change in investment over 1-year.
PRF Technologies's 1-Year ROIIC % for the quarter that ended in Jun. 2026 was 528.05%. High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
The industry rank for PRF Technologies's 1-Year ROIIC % or its related term are showing as below:
PRFX's 1-Year ROIIC % is ranked better than 96.14% of 828
companies
in the Drug Manufacturers industry
Industry Median: 1.595
vs PRFX: 528.05
Return on Incremental Invested Capital (ROIIC) is an extension of Return on Investment Capital (ROIC). ROIC % tells investors how efficiently that profitability is earned per dollar of company capital. ROIIC narrows the focus even further and shows how profitable each additional unit of capital investment could be. ROIIC % is a more powerful metric than ROIC because it measures how much money the company can generate going forward on future capital investments.
High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
Be Aware
It's important to keep in mind that when tracking ROIIC, the metric is better suited to forecasting the trend of future returns rather than measuring current return on investment.
PRF Technologies 1-Year ROIIC % Related Terms
PRF Technologies 1-Year ROIIC % Historical Data
* Premium members only.
The historical data trend for PRF Technologies's 1-Year ROIIC % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
PRFX vs CTTH, UPC, AKAN: 1-Year ROIIC % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, PRF Technologies's 1-Year ROIIC %, along with its competitors' market caps and 1-Year ROIIC % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
PRF Technologies 1-Year ROIIC % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, PRF Technologies's 1-Year ROIIC % distribution charts can be found below:
* The bar in red indicates where PRF Technologies's 1-Year ROIIC % falls into.
PRF Technologies's 1-Year ROIIC % for the quarter that ended in Jun. 2026 is calculated as:
1-Year ROIIC %
=
1-Year Incremental Net Operating Profit After Taxes (NOPAT)**
/
1-Year Incremental Invested Capital
=
( -5.294 (Jun. 2026) - -4.127 (Jun. 2025) )
/
( 7.493 (Jun. 2026) - 7.714 (Jun. 2025) )
=
-1.167
/
-0.221
=
528.05%***
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
** TTM data of NOPAT and Invested Capital was used to calculate 1-Year ROIIC %.
*** Please be aware that the ROIIC (Return on Invested Capital) calculations are based on company-level data using the primary share class. The calculated data provided is for demonstration purposes and may slightly differ from the results displayed in the title due to potential variations caused by currency exchange rate differences throughout the year.
PRF Technologies (PRFX) has a 1-Year ROIIC % of 528.05 as of Jun. 2026. 1-Year ROIIC % measures the change in earnings as a percentage of change in investment over 1-year. View historical data on PRF Technologies and its competitors. According to the industry distribution chart, PRF Technologies ranks #32 out of 828 companies in the Drug Manufacturers industry, placing it in the top 3.9%.
Is PRF Technologies' 1-Year ROIIC % too high?
PRF Technologies' current 1-Year ROIIC % is 528.05. The Drug Manufacturers industry median 1-Year ROIIC % is 1.60. PRF Technologies' value of 528.05 is 33006.6% above this industry median. Based on the distribution chart, PRF Technologies ranks #32 out of 828 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, PRF Technologies has a GF Score™ of 22/100, reflecting its overall financial health beyond just this single metric.
How does PRF Technologies' 1-Year ROIIC % compare to CTTH and UPC?
According to the Drug Manufacturers industry distribution chart, PRF Technologies ranks #32 out of 828 companies for 1-Year ROIIC %. This places PRF Technologies in the top 4% of its industry — outperforming the majority of peers. The industry median 1-Year ROIIC % is 1.60. PRF Technologies' value of 528.05 is 33006.6% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 1-Year ROIIC % for a Drug Manufacturers company?
The median 1-Year ROIIC % among Drug Manufacturers companies is 1.60, based on 828 companies in the industry. Companies in the top quartile (top 25%) have a 1-Year ROIIC % significantly above this median, while those in the bottom quartile fall well below. However, 1-Year ROIIC % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. PRF Technologies's current 1-Year ROIIC % of 528.05 is 33006.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 1-Year ROIIC % mean?
A high 1-Year ROIIC % can signal that a stock is expensive relative to its fundamentals. 1-Year ROIIC % measures the change in earnings as a percentage of change in investment over 1-year. View historical data on PRF Technologies and its competitors. For the Drug Manufacturers industry, the median 1-Year ROIIC % is 1.60 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. PRF Technologies's current 1-Year ROIIC % is 528.05. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is PRF Technologies stock overvalued right now?
PRF Technologies (PRFX) has a current 1-Year ROIIC % of 528.05. The current 1-Year ROIIC % is 528.05 and 33006.6% above the Drug Manufacturers industry median of 1.60. PRF Technologies' overall GF Score™ is 22/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 1-Year ROIIC % calculated?
1-Year ROIIC % is calculated from a company's financial statements. For PRF Technologies (PRFX), the current 1-Year ROIIC % is 528.05 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
PRF Technologies Ltd is a a diversified platform spanning speciality pharmaceuticals, drug-delivery technologies, and AI-driven renewable-energy analytics. PRF Technologies focuses on pharmaceutical therapies that emphasize reformulation and sustained-release drug-delivery technologies and AI-driven energy analytics. PRF-110, the company's lead product, is based on the local anesthetic ropivacaine and targets the postoperative pain relief market. The company has two operating segments composed of the Clinical Development segment, which facilitates the development of potential new drug compounds, and the Solar segment, which comprises the design and development of the company's intellectual property and the sale related service offerings.
22GF Score
Get the complete analysis for PRFX
1-Year ROIIC % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
PRFX has been successfully added to your 
